CA2534186A1 - Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides - Google Patents

Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides Download PDF

Info

Publication number
CA2534186A1
CA2534186A1 CA002534186A CA2534186A CA2534186A1 CA 2534186 A1 CA2534186 A1 CA 2534186A1 CA 002534186 A CA002534186 A CA 002534186A CA 2534186 A CA2534186 A CA 2534186A CA 2534186 A1 CA2534186 A1 CA 2534186A1
Authority
CA
Canada
Prior art keywords
seq
acid sequence
shows
sequence
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002534186A
Other languages
English (en)
Inventor
Kevin P. Baker
Jian Chen
Luc Desnoyers
Audrey Goddard
Paul J. Godowski
Austin L. Gurney
James Pan
Victoria Smith
Colin K. Watanabe
William I. Wood
Zemin Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech, Inc.
Kevin P. Baker
Jian Chen
Luc Desnoyers
Audrey Goddard
Paul J. Godowski
Austin L. Gurney
James Pan
Victoria Smith
Colin K. Watanabe
William I. Wood
Zemin Zhang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2000/005601 external-priority patent/WO2000056889A2/fr
Priority claimed from PCT/US2000/005841 external-priority patent/WO2000053758A2/fr
Priority claimed from PCT/US2000/006884 external-priority patent/WO2001005972A1/fr
Priority claimed from PCT/US2000/008439 external-priority patent/WO2000073454A1/fr
Priority claimed from PCT/US2000/013705 external-priority patent/WO2000073445A2/fr
Priority claimed from PCT/US2000/014042 external-priority patent/WO2000077037A2/fr
Priority claimed from PCT/US2000/014941 external-priority patent/WO2000073348A2/fr
Priority claimed from PCT/US2000/015264 external-priority patent/WO2000073452A2/fr
Priority claimed from PCT/US2000/020710 external-priority patent/WO2001009327A2/fr
Priority claimed from PCT/US2000/023328 external-priority patent/WO2001016318A2/fr
Priority claimed from PCT/US2000/030952 external-priority patent/WO2001049715A2/fr
Priority claimed from PCT/US2000/032678 external-priority patent/WO2001040466A2/fr
Priority claimed from PCT/US2000/034956 external-priority patent/WO2001046420A2/fr
Application filed by Genentech, Inc., Kevin P. Baker, Jian Chen, Luc Desnoyers, Audrey Goddard, Paul J. Godowski, Austin L. Gurney, James Pan, Victoria Smith, Colin K. Watanabe, William I. Wood, Zemin Zhang filed Critical Genentech, Inc.
Publication of CA2534186A1 publication Critical patent/CA2534186A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
CA002534186A 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides Abandoned CA2534186A1 (fr)

Applications Claiming Priority (80)

Application Number Priority Date Filing Date Title
USPCT/US00/05601 2000-03-01
PCT/US2000/005601 WO2000056889A2 (fr) 1999-03-23 2000-03-01 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci
USPCT/US00/05841 2000-03-02
PCT/US2000/005841 WO2000053758A2 (fr) 1999-03-08 2000-03-02 Compositions et methodes de traitement des maladies immunitaires
US18720200P 2000-03-03 2000-03-03
US60/187,202 2000-03-03
US18696800P 2000-03-06 2000-03-06
US60/186,968 2000-03-06
US18932000P 2000-03-14 2000-03-14
US18932800P 2000-03-14 2000-03-14
US60/189,320 2000-03-14
US60/189,328 2000-03-14
PCT/US2000/006884 WO2001005972A1 (fr) 1999-07-20 2000-03-15 Compositions et methodes pour traiter des maladies d'ordre immunologique
USPCT/US00/06884 2000-03-15
US19082800P 2000-03-21 2000-03-21
US19131400P 2000-03-21 2000-03-21
US19100700P 2000-03-21 2000-03-21
US19104800P 2000-03-21 2000-03-21
US60/191,007 2000-03-21
US60/190,828 2000-03-21
US60/191,314 2000-03-21
US60/191,048 2000-03-21
US19265500P 2000-03-28 2000-03-28
US60/192,655 2000-03-28
US19303200P 2000-03-29 2000-03-29
US19305300P 2000-03-29 2000-03-29
US60/193,053 2000-03-29
US60/193,032 2000-03-29
USPCT/US00/08439 2000-03-30
PCT/US2000/008439 WO2000073454A1 (fr) 1999-06-02 2000-03-30 Polypeptides transmembranaires secretes et acides nucleiques codants pour ceux-ci
US19444900P 2000-04-04 2000-04-04
US19464700P 2000-04-04 2000-04-04
US60/194,647 2000-04-04
US60/194,449 2000-04-04
US19600000P 2000-04-11 2000-04-11
US19682000P 2000-04-11 2000-04-11
US19669000P 2000-04-11 2000-04-11
US19597500P 2000-04-11 2000-04-11
US19618700P 2000-04-11 2000-04-11
US60/196,820 2000-04-11
US60/196,000 2000-04-11
US60/196,187 2000-04-11
US60/195,975 2000-04-11
US60/196,690 2000-04-11
US19858500P 2000-04-18 2000-04-18
US19812100P 2000-04-18 2000-04-18
US60/198,585 2000-04-18
US60/198,121 2000-04-18
US19955000P 2000-04-25 2000-04-25
US19965400P 2000-04-25 2000-04-25
US19939700P 2000-04-25 2000-04-25
US60/199,397 2000-04-25
US60/199,654 2000-04-25
US60/199,550 2000-04-25
US20151600P 2000-05-03 2000-05-03
US60/201,516 2000-05-03
PCT/US2000/013705 WO2000073445A2 (fr) 1999-06-02 2000-05-17 Promotion ou inhibition de l'angiogenese et de la cardiovascularisation
USPCT/US00/13705 2000-05-17
USPCT/US00/14042 2000-05-22
PCT/US2000/014042 WO2000077037A2 (fr) 1999-06-15 2000-05-22 Polypeptides secretes et transmembranaires et acides nucleiques les codant
USPCT/US00/14941 2000-05-30
PCT/US2000/014941 WO2000073348A2 (fr) 1999-06-02 2000-05-30 Procedes et compositions visant a inhiber la proliferation des cellules cancereuses
USPCT/US00/15264 2000-06-02
PCT/US2000/015264 WO2000073452A2 (fr) 1999-06-02 2000-06-02 Compositions et methodes de traitement de maladies liees a l'immunite
US20983200P 2000-06-05 2000-06-05
US60/209,832 2000-06-05
PCT/US2000/020710 WO2001009327A2 (fr) 1999-07-28 2000-07-28 Procede de prevention de la deterioration ou de la mort des cellules de la retine et de traitement des troubles oculaires
USPCT/US00/20710 2000-07-28
US64484800A 2000-08-22 2000-08-22
US09/644,848 2000-08-22
USPCT/US00/23328 2000-08-24
PCT/US2000/023328 WO2001016318A2 (fr) 1999-09-01 2000-08-24 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci
PCT/US2000/030952 WO2001049715A2 (fr) 2000-01-06 2000-11-08 Methodes et compositions permettant d'inhiber la croissance cellulaire neoplasique
USPCT/US00/30952 2000-11-08
USPCT/US00/32678 2000-12-01
PCT/US2000/032678 WO2001040466A2 (fr) 1999-12-01 2000-12-01 Polypeptides secretes et transmembranaires et acides nucleiques codant ces polypeptides
USPCT/US00/34956 2000-12-20
PCT/US2000/034956 WO2001046420A2 (fr) 1999-12-23 2000-12-20 Polypeptides homologues de l'il-17 et leurs utilisations therapeutiques
CA002401448A CA2401448A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
US60/000,000 2001-10-26

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA002401448A Division CA2401448A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides

Publications (1)

Publication Number Publication Date
CA2534186A1 true CA2534186A1 (fr) 2001-09-20

Family

ID=40231083

Family Applications (10)

Application Number Title Priority Date Filing Date
CA002534391A Abandoned CA2534391A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
CA002531917A Abandoned CA2531917A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
CA002539214A Abandoned CA2539214A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
CA002534018A Abandoned CA2534018A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
CA002534030A Abandoned CA2534030A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
CA002401448A Abandoned CA2401448A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
CA002533831A Abandoned CA2533831A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
CA002533903A Abandoned CA2533903A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
CA002534186A Abandoned CA2534186A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
CA002533991A Abandoned CA2533991A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant lesdits polypeptides

Family Applications Before (8)

Application Number Title Priority Date Filing Date
CA002534391A Abandoned CA2534391A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
CA002531917A Abandoned CA2531917A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
CA002539214A Abandoned CA2539214A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
CA002534018A Abandoned CA2534018A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
CA002534030A Abandoned CA2534030A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
CA002401448A Abandoned CA2401448A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
CA002533831A Abandoned CA2533831A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
CA002533903A Abandoned CA2533903A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA002533991A Abandoned CA2533991A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant lesdits polypeptides

Country Status (5)

Country Link
EP (1) EP1259614A2 (fr)
JP (3) JP2004508805A (fr)
AU (2) AU6802801A (fr)
CA (10) CA2534391A1 (fr)
WO (1) WO2001068848A2 (fr)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7057017B2 (en) 1997-04-16 2006-06-06 Millennium Pharmaceuticals, Inc. Human dickkopf-related protein and nucleic acid molecules and uses therefor
JP2001514885A (ja) 1997-08-19 2001-09-18 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ７０個のヒト分泌タンパク質
WO1999013078A1 (fr) 1997-09-12 1999-03-18 Biogen, Inc. Recepteurs 'train' riches en cysteine
US6849719B2 (en) 1997-09-17 2005-02-01 Human Genome Sciences, Inc. Antibody to an IL-17 receptor like protein
US6635443B1 (en) * 1997-09-17 2003-10-21 Human Genome Sciences, Inc. Polynucleotides encoding a novel interleukin receptor termed interleukin-17 receptor-like protein
US20030039648A1 (en) 1998-09-16 2003-02-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20030130182A1 (en) * 1997-11-05 2003-07-10 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7446181B2 (en) 1998-01-15 2008-11-04 Millennium Pharmaceuticals, Inc. Antibodies that bind human Dickkopf-1 proteins
US7771719B1 (en) 2000-01-11 2010-08-10 Genentech, Inc. Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E
ES2292242T5 (es) 1998-05-15 2011-05-04 Genentech, Inc. Utilizaciones terapéuticas de polipéptidos homólogos de il-17.
US6344541B1 (en) 1998-09-25 2002-02-05 Amgen Inc. DKR polypeptides
US6291663B1 (en) * 1999-03-03 2001-09-18 Board Of Trustees Of The University Of Arkansas TADG-12: a novel transmembrane serine protease overexpressed in a ovarian carcinoma
US7465785B2 (en) 1999-03-08 2008-12-16 Genentech, Inc. Polypeptide encoded by a nucleic acid over-expressed in melanoma
US8133734B2 (en) 1999-03-16 2012-03-13 Human Genome Sciences, Inc. Kit comprising an antibody to interleukin 17 receptor-like protein
AU5007200A (en) * 1999-05-13 2000-12-05 Medical Research Council Ox2 receptor homologs
EP1623993A3 (fr) * 1999-09-01 2006-06-07 Genetech, Inc. Protéines sécrétées et transmembranaire et acides nucléiques les codant
WO2001036604A2 (fr) 1999-11-18 2001-05-25 Corvas International, Inc. Acides nucleiques codant pour des endotheliases, endotheliases et leurs utilisations
DK1897945T3 (da) * 1999-12-23 2012-05-07 Genentech Inc IL-17 homologe polypeptider og terapeutiske anvendelser deraf.
US20040043397A1 (en) 2000-01-11 2004-03-04 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
WO2002000857A2 (fr) * 2000-06-15 2002-01-03 Millennium Pharmaceuticals, Inc. Acyltransférase humaine 53320 nouvellement découverte et ses utilisations
US7094566B2 (en) 2000-03-16 2006-08-22 Amgen Inc., IL-17 receptor like molecules and uses thereof
US7718397B2 (en) 2000-03-21 2010-05-18 Genentech, Inc. Nucleic acids encoding receptor for IL-17 homologous polypeptides and uses thereof
AU2001259271A1 (en) 2000-04-28 2001-11-12 Millennium Pharmaceuticals, Inc. 14094, a novel human trypsin family member and uses thereof
US20030096969A1 (en) 2000-06-02 2003-05-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
ATE385504T1 (de) 2000-06-06 2008-02-15 Bristol Myers Squibb Co Nukleinsäuren und polypeptide, die sich auf b7 beziehen und ihre verwendungen zur immunmodulierung
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
JP2004500872A (ja) * 2000-06-22 2004-01-15 バイオジェン　インコーポレイテッド Ｇｐ３５４核酸およびポリペプチド
US20020061574A1 (en) * 2000-09-01 2002-05-23 Rachel Meyers 16658, 14223, and 16002, novel human kinases and uses therefor
EP1294885A2 (fr) * 2000-06-30 2003-03-26 Amgen, Inc. Molecules de type b7 et utilisation de ces molecules
JP2004527210A (ja) 2000-08-02 2004-09-09 ザ ジョンズ ホプキンス ユニバーシティー 内皮細胞発現パターンの評価法
AU2001229503A1 (en) * 2000-08-28 2002-03-13 Human Genome Sciences, Inc. 17 human secreted proteins
AU2001294703A1 (en) * 2000-09-25 2002-04-08 Millennium Pharmaceuticals, Inc. 32624 a novel human udp-glucuronosyl and glycosyl transferase family member and uses thereof
HUP0600776A2 (en) 2000-11-14 2007-01-29 Bristol Myers Squibb Co A human serpin secreted from lymphoid cells lsi-01
DE10106835A1 (de) * 2001-02-14 2002-09-05 Basf Lynx Bioscience Ag Signaltransduktionsproteine 15B3, 15B3-1 und 15B3-2 und zugrundeliegende DNA-Sequenzen
JPWO2002064769A1 (ja) * 2001-02-15 2004-06-17 塩野義製薬株式会社 新規疾患マーカー
EP1873245A1 (fr) * 2001-02-28 2008-01-02 Genentech, Inc. Polypeptides homologue à l'interleukine-8 et utilisations thérapeutiques correspondantes
JP2004533222A (ja) * 2001-03-12 2004-11-04 インサイト・ゲノミックス・インコーポレイテッド 免疫グロブリンスーパーファミリータンパク質
CA2443123A1 (fr) 2001-04-10 2002-10-24 Agensys, Inc. Acides nucleiques et proteines correspondantes utiles pour la detection et le traitement de divers cancers
AU2002258780A1 (en) 2001-04-11 2002-10-28 Bristol-Myers Squibb Company Polynucleotides encoding two novel human g-protein coupled receptors, hgprbmy28 and hgprbmy29, and splice variants thereof
US7125663B2 (en) 2001-06-13 2006-10-24 Millenium Pharmaceuticals, Inc. Genes, compositions, kits and methods for identification, assessment, prevention, and therapy of cervical cancer
CA2451271A1 (fr) * 2001-06-22 2003-01-03 Alexander V. Lukashin Acides nucleiques et polypeptides pancam
WO2003004530A1 (fr) * 2001-07-06 2003-01-16 Bayer Aktiengesellschaft Régulation de la protéine semblable à un récepteur de la somatostatine humaine
JP2005502332A (ja) * 2001-07-26 2005-01-27 ジェンセット ソシエテ アノニム Ｇｍｇ−２ポリヌクレオチド及びポリペプチド並びにそれらの使用
JP4702819B2 (ja) 2001-08-01 2011-06-15 生化学工業株式会社 コンドロイチン合成酵素
US7262026B2 (en) 2001-08-23 2007-08-28 Japan Science And Technology Agency Hematopoietic stem cell proliferation regulators and polynucleotides encoding the same
ES2390531T3 (es) 2001-09-18 2012-11-13 Genentech, Inc. Composiciones y procedimientos para el diagnósitco y tratamiento de tumor
WO2003025162A2 (fr) * 2001-09-20 2003-03-27 Bayer Healthcare Ag Regulation du precurseur de la sous-unite alpha de prolyl 4-hydroxylase humaine
EP1469877A4 (fr) * 2001-11-02 2008-08-20 Tanox Inc Antigene specifique du lymphome des lymphocytes b destine a etre utilise dans le diagnostic et le traitement des malignites des lymphocytes b
AU2002359815A1 (en) 2001-12-19 2003-07-09 Immunex Corporation C-type lectin polypeptide, polynucleotide and methods of making and use thereof
DE10211088A1 (de) * 2002-03-13 2003-09-25 Ugur Sahin Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
MXPA04010091A (es) * 2002-04-17 2004-12-13 Genentech Inc Composiciones y metodos para el diagnostico y tratamiento de tumores.
EP2275118A3 (fr) 2002-05-29 2011-10-19 DeveloGen Aktiengesellschaft Proteines specifiques du pancreas
DE60319529T2 (de) * 2002-05-31 2008-10-23 Seikagaku Corp. Chondroitinsynthetase und das enzym codierende nukleinsäure
AU2003241979A1 (en) * 2002-05-31 2003-12-19 Hidetoshi Inoko Inflammatory skin disease-related slurp-2 gene and utilization thereof
EP2305710A3 (fr) 2002-06-03 2013-05-29 Genentech, Inc. Bibliothèques de phages et anticorps synthétiques
CA2497337A1 (fr) * 2002-09-11 2004-03-25 Genentech, Inc. Nouvelle composition et nouveaux procedes pour le traitement du psoriasis
DE10242016A1 (de) * 2002-09-11 2004-03-25 Esplora GmbH c/o TU Darmstadt Institut für Biochemie Verfahren zur Identifizierung BHS-spezifischer Proteine und Fragmente davon
DE10254601A1 (de) * 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
AU2003292774A1 (en) * 2002-12-26 2004-07-22 Takeda Pharmaceutical Company Limited Novel proteins and use thereof
AU2003302753A1 (en) * 2002-12-27 2004-08-10 Laboratoires Serono Sa Novel fibrillin-like polypeptides
US20060089297A1 (en) * 2003-01-16 2006-04-27 Herr John C Sperm specific lysozyme-like proteins
US7312197B2 (en) 2003-02-24 2007-12-25 University Of Maryland, Baltimore Method of modifying glucose activity using polypeptides selectively expressed in fat tissue
US20040185559A1 (en) 2003-03-21 2004-09-23 Isis Pharmaceuticals Inc. Modulation of diacylglycerol acyltransferase 1 expression
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
KR100835786B1 (ko) 2003-07-08 2008-06-09 제넨테크, 인크. Ｉｌ-１７ａ／ｆ 이종 폴리펩티드 및 그의 치료 용도
AU2004266246A1 (en) 2003-08-14 2005-03-03 Dyax Corp. Endotheliase-2 ligands
US7825235B2 (en) 2003-08-18 2010-11-02 Isis Pharmaceuticals, Inc. Modulation of diacylglycerol acyltransferase 2 expression
WO2005061704A1 (fr) * 2003-12-24 2005-07-07 Takeda Pharmaceutical Company Limited Substance destinee a la prevention et au traitement du cancer
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
WO2006014335A2 (fr) 2004-07-02 2006-02-09 Genentech, Inc. Compositions et procedes pour le traitement de lymphome non hodgkinien
CN101014245A (zh) 2004-08-03 2007-08-08 比奥根艾迪克Ma公司 神经元功能中的taj
US7709611B2 (en) 2004-08-04 2010-05-04 Amgen Inc. Antibodies to Dkk-1
US7544659B2 (en) 2004-08-13 2009-06-09 Genentech, Inc. Promotion of axonal regeneration
JP2008532516A (ja) * 2005-03-11 2008-08-21 ジェネンテック・インコーポレーテッド 遺伝子破壊、組成物、およびそれに関連する方法
EP1790664A1 (fr) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Anticorps monoclonaux contre claudin-18 pour le traitement du cancer
NZ568015A (en) 2005-12-08 2012-03-30 Medarex Inc Human monoclonal antibodies to O8E
WO2007107774A2 (fr) * 2006-03-22 2007-09-27 Cartela R & D Ab Nouvelles méthodes de diagnostic et de traitement
US20090288176A1 (en) * 2006-04-19 2009-11-19 Genentech, Inc. Novel Gene Disruptions, Compositions and Methods Relating Thereto
EP2057177B1 (fr) 2006-08-04 2012-11-21 Isis Pharmaceuticals, Inc. Compositions et leurs utilisations dirigées sur la diacylglycérol acyltransférase 1
EP2069793B9 (fr) 2006-08-29 2017-08-16 Oxford BioTherapeutics Ltd Identification d'une protéine associée à un carcinome hépatocellulaire, à un glioblastome et à un cancer du poumon
US8058014B2 (en) 2006-09-29 2011-11-15 University Of Maryland, Baltimore Method of diagnosing or predicting disease states in a subject using omentin 1 and omentin 2
CN104628855A (zh) 2008-05-05 2015-05-20 诺维莫尼公司 抗il-17a/il-17f交叉反应性抗体及其使用方法
CA2726804C (fr) * 2008-06-02 2021-12-28 Dana-Farber Cancer Institute, Inc. Peptides derives de xbp1, cd138 et cs1
MX2011009220A (es) 2009-03-05 2011-09-28 Medarex Inc Anticuerpos completamente humanos especificos para la molecula de adhesion celular 1.
AU2010244142B2 (en) 2009-05-05 2016-07-21 Novimmune Sa Anti-IL-17F antibodies and methods of use thereof
WO2013167153A1 (fr) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Anticorps utiles dans le diagnostic du cancer
WO2013174404A1 (fr) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Polythérapie impliquant des anticorps dirigés contre la claudine 18,2 pour le traitement du cancer
EP2914278B1 (fr) 2012-11-05 2021-06-02 Dana-Farber Cancer Institute, Inc. Xbp1, cd138 et cs1, compositions pharmaceutiques qui comprennent les peptides et procédés d'utilisation de tels peptides et compositions
US10093736B2 (en) 2012-11-13 2018-10-09 Biontech Ag Agents for treatment of claudin expressing cancer diseases
WO2014127785A1 (fr) 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Polythérapie impliquant des anticorps dirigés contre la claudine 18,2 pour le traitement du cancer
WO2014146672A1 (fr) 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Thérapie comprenant des anticorps dirigés contre cldn 18.2 pour le traitement du cancer
ES2917181T3 (es) 2015-07-10 2022-07-07 Ionis Pharmaceuticals Inc Moduladores de diacilglicerol aciltransferasa 2 (DGAT2)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000073454A1 (fr) * 1999-06-02 2000-12-07 Genentech, Inc. Polypeptides transmembranaires secretes et acides nucleiques codants pour ceux-ci
WO1999063088A2 (fr) * 1998-06-02 1999-12-09 Genentech, Inc. Proteines membranaires et acides nucleiques codant ces proteines
DE19817948A1 (de) * 1998-04-17 1999-10-21 Metagen Gesellschaft Fuer Genomforschung Mbh Menschliche Nukleinsäuresequenzen aus Endometrium-Tumor
JP2004507202A (ja) * 1999-03-31 2004-03-11 キュラジェン　コーポレイション ポリペプチドをコードするオープンリーディングフレームを含む核酸；「ｏｒｆｘ」
EP1248800A2 (fr) * 1999-11-30 2002-10-16 Corixa Corporation Compositions et methodes destinees au traitement et au diagnostic du cancer du sein
WO2001057190A2 (fr) * 2000-02-03 2001-08-09 Hyseq, Inc. Acides nucleiques et polypeptides
KR20030029847A (ko) * 2000-08-24 2003-04-16 제넨테크, 인크. 종양의 진단 및 치료를 위한 조성물 및 방법

Also Published As

Publication number Publication date
AU2001268028A1 (en) 2001-09-24
CA2534391A1 (fr) 2001-09-20
AU6802801A (en) 2001-09-24
WO2001068848A2 (fr) 2001-09-20
JP2004508805A (ja) 2004-03-25
CA2539214A1 (fr) 2001-09-20
JP2008301822A (ja) 2008-12-18
CA2533991A1 (fr) 2001-09-20
CA2533903A1 (fr) 2001-09-20
CA2531917A1 (fr) 2001-09-20
CA2534030A1 (fr) 2001-09-20
CA2401448A1 (fr) 2001-09-20
CA2534018A1 (fr) 2001-09-20
JP2006081548A (ja) 2006-03-30
EP1259614A2 (fr) 2002-11-27
WO2001068848A3 (fr) 2002-08-29
CA2533831A1 (fr) 2001-09-20

Similar Documents

Publication Publication Date Title
US7189838B2 (en) PRO9834 nucleic acids
US7087421B2 (en) Pro1278 polypeptides
CA2534186A1 (fr) Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
US7084255B2 (en) PRO1278 polypeptides
US20040023321A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030104548A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030104547A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030104551A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead